J Gynecol Oncol.
2023 Mar;34(2):e51. 10.3802/jgo.2023.34.e51.
Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
- 2Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 3Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
- 4Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea
- 5Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea
- 6Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea
- 7Department of Obstetrics and Gynecology, Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea
- 8Department of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, Korea
- 9Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea
- KMID: 2552526
- DOI: http://doi.org/10.3802/jgo.2023.34.e51
Abstract
- In the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-up data, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival (OS) issues with PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate; 2) Cervical cancer: surgery in early stage disease, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpus cancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibitor, selective inhibitor of nuclear export. A special note was made on the withdrawal of PARP inhibitor from the market for heavily pretreated ovarian cancer patients based on the final OS results of ARIEL-4 and SOLO-3 due to concerns of increased risk of death.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective
- The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
- Interleukin-34 cancels anti-tumor immunity by PARP inhibitor
- Assessment and research of quality of life in gynecologic cancer patients
- Major clinical research advances in gynecologic cancer in 2021
